AKTS — Aktis Oncology, Inc.
Median target
$35
calls from the last 12 months
Implied return
+134.3%
median target vs. price
Coverage
8 analysts · 9 calls
updated in the last 12 months
Consensus
8/0/0+8 net
Buy / Hold / Sell
Which analysts are behind AKTS's consensus?
See every current rating, price target and the analysts' track records for Aktis Oncology, Inc. — plus the full analyst rankings, firm analytics and screener.
The consensus above reflects 8 analysts with calls on AKTS updated in the last 12 months. Implied return is the move implied if the consensus target were hit. These are forward-looking predictions, not realized returns. Per-analyst ratings and track records are a Premium feature.
AKTS elsewhere on AnalystEdge
The most recent congressional, executive-branch and insider filings matched to this ticker. Matched by ticker symbol — occasional mismatches are possible. Not investment advice.
Trending today: not in any of today's trending tables (Gaining attention, Losing attention, Most followed)
| Date | Source | Who | Action | Detail | Amount |
|---|---|---|---|---|---|
| 2026-09-23 | Insiders | Czibere AkosOfficer | Insider sale | 7.4K sh @ $21.03 · planned trade | $156K |
| 2026-09-23 | Insiders | Czibere AkosOfficer | Insider sale | 5.1K sh @ $20.19 · planned trade | $103K |
More: insider activity · executive branch · trending